Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients.

Chadli L, Sotthewes B, Li K, Andersen SN, Cahir-McFarland E, Cheung M, Cullen P, Dorjée A, de Vries-Bouwstra JK, Huizinga TWJ, Fischer DF, DeGroot J, Viney JL, Zheng TS, Aarbiou J, Gardet A.

Sci Rep. 2019 Mar 14;9(1):4521. doi: 10.1038/s41598-019-41153-w.

2.

Pristane-Accelerated Autoimmune Disease in (SWR X NZB) F1 Mice Leads to Prominent Tubulointerstitial Inflammation and Human Lupus Nephritis-Like Fibrosis.

Gardet A, Chou WC, Reynolds TL, Velez DB, Fu K, Czerkowicz JM, Bajko J, Ranger AM, Allaire N, Kerns HM, Ryan S, Legault HM, Dunstan RW, Lafyatis R, Lukashev M, Viney JL, Browning JL, Rabah D.

PLoS One. 2016 Oct 19;11(10):e0164423. doi: 10.1371/journal.pone.0164423. eCollection 2016.

3.

Discovery of biaryl carboxylamides as potent RORγ inverse agonists.

Chao J, Enyedy I, Van Vloten K, Marcotte D, Guertin K, Hutchings R, Powell N, Jones H, Bohnert T, Peng CC, Silvian L, Hong VS, Little K, Banerjee D, Peng L, Taveras A, Viney JL, Fontenot J.

Bioorg Med Chem Lett. 2015 Aug 1;25(15):2991-7. doi: 10.1016/j.bmcl.2015.05.026. Epub 2015 May 23.

PMID:
26048806
4.

Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms.

Pellerin A, Otero K, Czerkowicz JM, Kerns HM, Shapiro RI, Ranger AM, Otipoby KL, Taylor FR, Cameron TO, Viney JL, Rabah D.

EMBO Mol Med. 2015 Apr;7(4):464-76. doi: 10.15252/emmm.201404719.

5.

GPR15: a tale of two species.

Bilsborough J, Viney JL.

Nat Immunol. 2015 Feb;16(2):137-9. doi: 10.1038/ni.3084. No abstract available.

PMID:
25594457
6.

Immune modulation by butyrophilins.

Arnett HA, Viney JL.

Nat Rev Immunol. 2014 Aug;14(8):559-69. doi: 10.1038/nri3715. Review.

PMID:
25060581
7.

Genetic architecture of human fibrotic diseases: disease risk and disease progression.

Gardet A, Zheng TS, Viney JL.

Front Pharmacol. 2013 Dec 18;4:159. doi: 10.3389/fphar.2013.00159. Review.

8.

Butyrophilin-like 2 modulates B7 costimulation to induce Foxp3 expression and regulatory T cell development in mature T cells.

Swanson RM, Gavin MA, Escobar SS, Rottman JB, Lipsky BP, Dube S, Li L, Bigler J, Wolfson M, Arnett HA, Viney JL.

J Immunol. 2013 Mar 1;190(5):2027-35. doi: 10.4049/jimmunol.1201760. Epub 2013 Jan 28.

9.

The tale of TL1A in inflammation.

Hsu H, Viney JL.

Mucosal Immunol. 2011 Jul;4(4):368-70. doi: 10.1038/mi.2011.20. Epub 2011 May 4. Review.

PMID:
21544073
10.

Gatekeepers of intestinal inflammation.

Arnett HA, Viney JL.

Inflamm Res. 2010 Jan;59(1):1-14. Review.

PMID:
20066780
11.

Methods of inducing inflammatory bowel disease in mice.

Maxwell JR, Brown WA, Smith CL, Byrne FR, Viney JL.

Curr Protoc Pharmacol. 2009 Dec;Chapter 5:Unit5.58. doi: 10.1002/0471141755.ph0558s47.

PMID:
22294404
12.

Overview of mouse models of inflammatory bowel disease and their use in drug discovery.

Maxwell JR, Viney JL.

Curr Protoc Pharmacol. 2009 Dec;Chapter 5:Unit5.57. doi: 10.1002/0471141755.ph0557s47. Review.

PMID:
22294403
13.

Recent developments in IBD and the B7 family of costimulatory molecules.

Arnett HA, Viney JL.

Curr Opin Investig Drugs. 2009 May;10(5):443-51. Review.

PMID:
19431077
14.

Regulation of costimulation in the era of butyrophilins.

Arnett HA, Escobar SS, Viney JL.

Cytokine. 2009 Jun;46(3):370-5. doi: 10.1016/j.cyto.2009.03.009. Epub 2009 Apr 19. Review.

PMID:
19380239
15.

Serum biomarkers in a mouse model of bacterial-induced inflammatory bowel disease.

Torrence AE, Brabb T, Viney JL, Bielefeldt-Ohmann H, Treuting P, Seamons A, Drivdahl R, Zeng W, Maggio-Price L.

Inflamm Bowel Dis. 2008 Apr;14(4):480-90.

PMID:
18095317
16.

Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic.

Arnett HA, Viney JL.

Adv Drug Deliv Rev. 2007 Sep 30;59(11):1084-92. Epub 2007 Aug 16. Review.

PMID:
17804112
17.

BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation.

Arnett HA, Escobar SS, Gonzalez-Suarez E, Budelsky AL, Steffen LA, Boiani N, Zhang M, Siu G, Brewer AW, Viney JL.

J Immunol. 2007 Feb 1;178(3):1523-33.

18.

From model to mechanism: lessons of mice and men in the discovery of protein biologicals for the treatment of inflammatory bowel disease.

Bilsborough J, Viney JL.

Expert Opin Drug Discov. 2006 Jun;1(1):69-83. doi: 10.1517/17460441.1.1.69.

PMID:
23506033
19.

Mouse models of inflammatory bowel disease.

Byrne FR, Viney JL.

Curr Opin Drug Discov Devel. 2006 Mar;9(2):207-17. Review.

PMID:
16566291
20.

Dual infection with Helicobacter bilis and Helicobacter hepaticus in p-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia.

Maggio-Price L, Bielefeldt-Ohmann H, Treuting P, Iritani BM, Zeng W, Nicks A, Tsang M, Shows D, Morrissey P, Viney JL.

Am J Pathol. 2005 Jun;166(6):1793-806.

21.
22.

In vivo enhancement of dendritic cell function.

Bilsborough J, Viney JL.

Ann N Y Acad Sci. 2004 Dec;1029:83-7. Review.

PMID:
15681747
23.

Out, out darn toxin: the role of MDR in intestinal homeostasis.

Bilsborough J, Viney JL.

Gastroenterology. 2004 Jul;127(1):339-40. Review. No abstract available.

PMID:
15236205
24.

Gastrointestinal dendritic cells play a role in immunity, tolerance, and disease.

Bilsborough J, Viney JL.

Gastroenterology. 2004 Jul;127(1):300-9. Review.

PMID:
15236195
25.
26.

High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro.

George TC, Bilsborough J, Viney JL, Norment AM.

Eur J Immunol. 2003 Feb;33(2):502-11.

27.

GM-CSF treatment for Crohn's disease: a stimulating new therapy?

Wilk JN, Viney JL.

Curr Opin Investig Drugs. 2002 Sep;3(9):1291-6. Review.

PMID:
12498002
29.

Defining the roles of perforin, Fas/FasL, and tumour necrosis factor alpha in T cell induced mucosal damage in the mouse intestine.

Merger M, Viney JL, Borojevic R, Steele-Norwood D, Zhou P, Clark DA, Riddell R, Maric R, Podack ER, Croitoru K.

Gut. 2002 Aug;51(2):155-63.

30.

Getting to the guts of immune regulation.

Bilsborough J, Viney JL.

Immunology. 2002 Jun;106(2):139-43. Review. No abstract available.

31.
32.

Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice.

Maggio-Price L, Shows D, Waggie K, Burich A, Zeng W, Escobar S, Morrissey P, Viney JL.

Am J Pathol. 2002 Feb;160(2):739-51.

33.

Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice.

Burich A, Hershberg R, Waggie K, Zeng W, Brabb T, Westrich G, Viney JL, Maggio-Price L.

Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G764-78.

34.

Immune fate decided by dendritic cell provocateurs.

Viney JL.

Trends Immunol. 2001 Jan;22(1):8-10. No abstract available.

PMID:
11334031
35.

The ins and outs of body surface immunology.

Hayday A, Viney JL.

Science. 2000 Oct 6;290(5489):97-100. Review.

PMID:
11021807
36.

Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice.

Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR, Brasel K, Morrissey PJ, Stocking K, Schuh JC, Joyce S, Peschon JJ.

J Exp Med. 2000 Mar 6;191(5):771-80.

37.

Dendritic cell subsets: the ultimate T cell differentiation decision makers?

Viney JL.

Gut. 1999 Nov;45(5):640-1. No abstract available.

38.

Modulating dendritic cells to optimize mucosal immunization protocols.

Williamson E, Westrich GM, Viney JL.

J Immunol. 1999 Oct 1;163(7):3668-75.

39.

Visualizing the T-cell response elicited by oral administration of soluble protein antigen.

Williamson E, O'Malley JM, Viney JL.

Immunology. 1999 Aug;97(4):565-72.

41.

Beta 7 integrins and their ligands in lymphocyte migration to the gut.

Viney JL, Fong S.

Chem Immunol. 1998;71:64-76. Review. No abstract available.

PMID:
9761947
42.

Altering cytokine soups: a recipe for inflammatory bowel disease?

Viney JL.

Gut. 1998 May;42(5):607-8. No abstract available.

43.

Expanding dendritic cells in vivo enhances the induction of oral tolerance.

Viney JL, Mowat AM, O'Malley JM, Williamson E, Fanger NA.

J Immunol. 1998 Jun 15;160(12):5815-25.

44.

The anatomical basis of intestinal immunity.

Mowat AM, Viney JL.

Immunol Rev. 1997 Apr;156:145-66. Review.

PMID:
9176706
45.

Mucosal addressin cell adhesion molecule-1: a structural and functional analysis demarcates the integrin binding motif.

Viney JL, Jones S, Chiu HH, Lagrimas B, Renz ME, Presta LG, Jackson D, Hillan KJ, Lew S, Fong S.

J Immunol. 1996 Sep 15;157(6):2488-97.

PMID:
8805649
46.

Immune responsiveness in mutant mice lacking T-cell receptor alpha beta+ cells.

Chandler P, Frater AJ, Douek DC, Viney JL, Kay G, Owen MJ, Hayday AC, Simpson E, Altmann DM.

Immunology. 1995 Aug;85(4):531-7.

47.

Transgenic and gene knockout mice in cancer research.

Viney JL.

Cancer Metastasis Rev. 1995 Jun;14(2):77-90. Review.

PMID:
7554032
48.

Lymphocyte proliferation in mice congenitally deficient in T-cell receptor alpha beta + cells.

Viney JL, Dianda L, Roberts SJ, Wen L, Mallick CA, Hayday AC, Owen MJ.

Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):11948-52.

49.

Immunoglobulin synthesis and generalized autoimmunity in mice congenitally deficient in alpha beta(+) T cells.

Wen L, Roberts SJ, Viney JL, Wong FS, Mallick C, Findly RC, Peng Q, Craft JE, Owen MJ, Hayday AC.

Nature. 1994 Jun 23;369(6482):654-8.

PMID:
8208291
50.

Transgenic and knockout models for studying diseases of the immune system.

Viney JL.

Curr Opin Genet Dev. 1994 Jun;4(3):461-5. Review.

PMID:
7919925

Supplemental Content

Loading ...
Support Center